Dr. Bernd Goergen

Partner

Dr. Bernd Goergen

Partner

Dr Bernd Goergen, Partner, has been a part of High-Tech Gründerfonds’ Life Science Team since early 2008. He holds a PhD in biology and is a certified biotech analyst with the German Association for Financial Analysis and Asset Management (DVFA). He brings with him five years of research experience in the field of virology and immunology and seven years in international diagnostics marketing for German and international companies. Between 2000 and 2007, Dr Goergen also acquired extensive knowledge in M&A and capital market deals while working in the investment banking division of a major German bank.

Contact

Telefon:
+49 –(0)228 – 82300 – 136

Portfolio

Posts & mentions

Press
18. January 2022

PreOmics Announces Early Investors’ Exit and Closing of Series B Financing to Accelerate R&D and Commercialization of Proteomics Tools and Consumables

PreOmics Offers Unique Technologies, Advanced Automation Solutions and High-Performance Consumables for the Homogenization, Enrichment and Proteomic Sample Preparation of Biopsy, Tissue, Cell Line and Plasma Samples in Unbiased, Deep Proteomics for Pharmaceutical and Clinical Research MUNICH, Germany – January 18, 2022 – PreOmics GmbH, a Martinsried, Germany-based developer of innovative automation and sample preparation tools and consumables for unbiased, deep proteomics analysis
 
Blog
Blog
16. December 2021

Important developments to watch out for in 2022

What trends does next year have in store for us? Five High-Tech Gründerfonds Partners take a look into the crystal ball, reveal the technologies they feel will become relevant, and explain why start-ups need to focus on corporate culture and employer branding from an early stage. Implementing good ideas very well In 2022 we’ll be looking beyond the pandemic. If the extreme developments are able to be kept in check, we could see the economy recovering and picking up quite r
 
Blog
Blog
18. December 2020

How passion and expertise led to a billion-euro exit

As a High-Tech Gründerfonds (HTGF) partner, Dr. Bernd Goergen has just signed the most successful exit in HTGF history. US pharmaceutical company Gilead Sciences is set to acquire German biotech start-up MYR for roughly EUR 1.15 billion. In this interview, he speaks about the fight against Hepatitis D, drug development and his own personal successes. Bernd, congratulations are in order! In 2011, HTGF took up a stake in MYR. And now you’re about to close a billion-eur
 
Press
10. December 2020

Most Successful Exit in the History of High-Tech Gründerfonds - Gilead Sciences to Acquire MYR GmbH

One of the largest trade sales of a VC-financed German biotech start-up in the last 20 yearsMYR developed HepcludexTM (Bulevirtide), a first-in-class entry inhibitor for the treatment of chronic hepatitis delta virus (HDV). Hepcludex was conditionally approved in Europe by the EMA in July 2020 and submission for accelerated approval in the United States is anticipated by second half of 2021The acquisition builds on Gilead’s strength as a global leader in virology and liver diseases with ad
 
Press
20. October 2020

Successful exit for High-Tech Gründerfonds and Bayern Kapital –
Proteintech acquires ChromoTek

Proteintech, which is based in Chicago, Illinois, USA, is the benchmark in antibodiesMartinsried-based startup ChromoTek is a market leader in nanobodiesThe acquisition enables Proteintech to expand its next-generation antibody toolsBayern Kapital and HTGF arranged the seed financing in 2010The transaction marks HTGF’s 10th successful exit during the coronavirus crisis High-Tech Gründerfonds and Bayern Kapital have sold their shares in ChromoTek after having spent 10 years at the start
 
Press
15. September 2020

Successful Exit for High-Tech Gründerfonds – Intersect ENT acquires Fiagon

Buyer is the Intersect ENT, a medical technology company based in the USThe startup Fiagon AG Medical Technologies expands Intersects portfolio of ENT product offeringsFor the HTGF it is the 8th successful exit during the Corona crisis The High-Tech Gründerfonds sold its shares in Fiagon. The seed investor has accompanied the company for 11 years. The publicly traded company Intersect ENT (NASDAQ: XENT), Menlo Park, California, USA, is dedicated to transforming  the treatment of ear